Proteins and Peptides
7 February 2013
Acorda Therapeutics Presents GGF2 Preclinical Stroke Data at International Stroke Conference6 February 2013
Derma Sciences Initiates Enrollment in DSC127 Phase 3 Trial for Healing Diabetic Foot Ulcers6 February 2013
Inspiration Biopharmaceuticals and Ipsen Complete Sale Process for All Hemophilia Assets5 February 2013
Hepatology Publishes 12-Week Phase I/II Extension Study Data of Sebelipase Alfa in Adults with Late Onset LAL Deficiency4 February 2013
Once-Daily Lyxumia (lixisenatide) Approved for Treatment of Type 2 Diabetes in Europe27 January 2013
Amgen Announces Results From Phase 3 PAVES Study Evaluating Neulasta (pegfilgrastim) In Patients With Colorectal Cancer24 January 2013
Biodel Reports Positive Top-Line Results From Clinical Study of Ultra-Rapid-Acting Insulin Analog Candidates24 January 2013
Biogen Idec Announces Positive Top-Line Results from Phase 3 Study of Peginterferon Beta-1a in Multiple Sclerosis22 January 2013
Nymox Announces New Positive Results in Phase 3 Repeat Injection Study of NX-1207 for BPH16 January 2013
Stealth Peptides Initiates Patient Enrollment for Novel Treatment of Acute Kidney Injury14 January 2013
GSK announces submission of albiglutide BLA to the US FDA for the treatment of type 2 diabetes8 January 2013
Baxter to Initiate Late-Stage Clinical Trial of BAX 855 for the Treatment of Hemophilia A8 January 2013
Aspireo Reports Somatoprim Phase I b Interim Data8 January 2013
Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog8 January 2013
FDA approves Kineret for the treatment of NOMIDNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports